Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Stock Price Down 3% – Here’s What Happened

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP)’s stock price was down 3% on Tuesday . The company traded as low as $2.22 and last traded at $2.28. Approximately 11,568 shares traded hands during mid-day trading, a decline of 6% from the average daily volume of 12,338 shares. The stock had previously closed at $2.35.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $7.00 price target on shares of Armata Pharmaceuticals in a research note on Thursday, August 15th.

Armata Pharmaceuticals Trading Up 0.9 %

The firm has a market cap of $81.04 million, a PE ratio of -0.95 and a beta of 0.80.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last announced its earnings results on Tuesday, August 13th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by ($0.13). Equities research analysts forecast that Armata Pharmaceuticals, Inc. will post -1.02 earnings per share for the current fiscal year.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.